MUKILTEO, Wash., Aug. 12, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that a retrospective, clinical validation study of its test for Chronic Lymphocytic Leukemia (CLL) is to be published in the September issue of the Journal of Molecular Diagnostics (J Mol Diagn 2008, 10:442-451). This publication augments an earlier publication in the Expert Opinions in Molecular Diagnostics ((2008) 2(6): 1-10). Dr. Shelly Gunn, M.D., Ph.D. Medical Director of CombiMatrix Molecular Diagnostics (CMDX), was the lead author of both publications.
